PHAT News and Press, Phathom Pharmaceuticals Inc. From 01/09/23

Phathom Pharmaceuticals ( NASDAQ: PHAT ), a biopharma focused on GIT disorders, traded higher on Monday after the company said a Phase 3 trial for its experimental heartburn therapy vonoprazan met the primary endpoint. Vonoprazan is designed to block acid secretion in the stomach. The...

Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001) Data expected to provide the basis for future regulatory submission for vonoprazan as a daily tre...

Phathom Pharmaceuticals ( NASDAQ: PHAT ) plunged 25% in after-hours trading on Tuesday after it was informed by the US FDA that the agency would not render a decision on its vonoprazan NDA for erosive esophagitis by the Jan. 11 PDUFA date . In early August 2022, the compa...

FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced that the U.S. Food and Drug Administration (FDA) ...

Summary PHAT, a Takeda spinoff, has a drug approved in H. pylori. The same drug has a PDUFA in a GERD subtype. The company is somewhat unexciting, being in a low-value market, however, it has some growth potential. Phathom Pharmaceuticals, Inc. ( PHAT ) develops ...

Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to an additional $40 million under revenue interest financing agreement; total financi...

FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of its management team will pa...

Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty payments capped at 2.0x invested capital Provides agreement for additional $15 million upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) ...

A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S. Topline data for the primary endpoint is expected in Q1 2023 with full trial results available in late-2023 NERD is the largest subcategory of gastroesoph...

FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that detailed results from an investigation...